Trial reportThe Journal of international medical research2018
Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial.
Trial report in The Journal of international medical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 73 citations in OpenAlex.
- Understanding the Inflammatory Aspect of Osteoarthritis: Lessons from Immune Checkpoint Inhibitors.Journal of clinical medicine · 2026Review
- Inflammaging and osteoarthritis - therapeutic opportunities.Frontiers in immunology · 2026Review
- Fibroblast-Myofibroblast Transition in Osteoarthritis Progression: Current Insights.International journal of molecular sciences · 2025Review
- Multiscale characterization of ultrasmall fluorescent core-shell silica nanoparticles in cartilage and synovial joints reveals rapid cartilage penetration and sustained joint residence.Acta biomaterialia · 2025Article
- Long-Acting Extracellular Vesicle-Based Biologics in Osteoarthritis Immunotherapy.Bioengineering (Basel, Switzerland) · 2025Review
- Article
- Development of a macrophage polarization-modulating therapeutic agent for osteoarthritis treatment.Journal of orthopaedic surgery and research · 2025Review
- Hydroxycitric acid reconstructs damaged articular cartilages by modifying the metabolic cascade in chondrogenic cells.Osteoarthritis and cartilage open · 2025Article
- Delivery of FGF18 using mRNA-LNP protects the cartilage against degeneration via alleviating chondrocyte senescence.Journal of nanobiotechnology · 2025Article
- Real-world individual and comparative analysis of adverse event reporting for adalimumab and etanercept using public FDA adverse event reporting system data.Archives of dermatological research · 2024Article
- Inflammation as a therapeutic target for osteoarthritis: A literature review of clinical trials.Clinical rheumatology · 2024Review
- Pathogenic Mechanisms and Therapeutic Approaches in Obesity-Related Knee Osteoarthritis.Biomedicines · 2023Review
- Mechanical overloading leads to chondrocyte degeneration and senescence via Zmpste24-mediated nuclear membrane instability.iScience · 2023Article
- The potential role of synovial cells in the progression and treatment of osteoarthritis.Exploration (Beijing, China) · 2023Review
- Inflammatory mechanisms in post-traumatic osteoarthritis: a role for CaMKK2.Immunometabolism (Cobham, Surrey) · 2023Review
- Methods of Conservative Intra-Articular Treatment for Osteoarthritis of the Hip and Knee.Deutsches Arzteblatt international · 2023Review
- Review
- Intra-articular nanoparticles based therapies for osteoarthritis and rheumatoid arthritis management.Materials today. Bio · 2023Article
- Outcomes of a QST Protocol in Healthy Subjects and Chronic Pain Patients: A Controlled Clinical Trial.Biomedicines · 2023Article
- Biomarkers of Osteoarthritis-A Narrative Review on Causal Links with Metabolic Syndrome.Life (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective To evaluate the efficacy and safety of adalimumab (ADA) versus hyaluronic acid (HA) by intra-articular injection for moderate to severe knee osteoarthritis. Methods Fifty-six consecutive patients with moderate to severe knee osteoarthritis were randomly allocated to either the ADA group or HA group. On day 0, patients in the ADA group received 10 mg of ADA by intra-articular injection, while those in the HA group received 25 mg of HA. All patients received celecoxib at 200 mg/day for 4 weeks. The pain visual analog scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Patient Global Assessment (PGA), and Physician Global Assessment (PhGA) scores were assessed. Results At baseline, the pain VAS, WOMAC, PGA, and PhGA scores were similar between the two groups. The decrease in the pain VAS score, WOMAC pain score, WOMAC physical function score, and WOMAC total score from baseline to week 4 were greater in the ADA than HA group. A greater decrease in the PGA and PhGA scores from baseline to week 4 was noted in the ADA than HA group. No difference in adverse events was observed between the two groups. Conclusion ADA by intra-articular injection was effective and tolerated for moderate to severe knee osteoarthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.